Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022
Certara, Inc. (Nasdaq: CERT) will announce its fourth quarter and full year 2021 financial results after market close on March 1, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT) will announce its fourth quarter and full year 2021 financial results after market close on March 1, 2022. A conference call hosted by company management will take place at 5:00 p.m. ET to discuss these results. Investors can join the call by dialing (833) 360-0946 for domestic calls or (914) 987-7661 for international calls, using Conference ID: 4688502. Additionally, a live and archived webcast of the call will be available on Certara's investor relations website.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was +3.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 4688502. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. Visit us at www.certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.